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Man. Some Miscellaneous Pharma-
ceutical Substances. Vol. 13. (1977)
Lyon: International Agency for Research
on Cancer. 255 pp. U.S.$12.00 net.
In 1971 the IARC began a programme to
publish a series ofmonographs on compounds
for which there was some suggestion of pos-
sible carcinogenicity for man. The data are
selected and evaluated by working groups of
about 12 experts. The result has been an
exceptionally useful authoritative series, with
a good clear layout, describing chemical
properties, production and use, occurrence,
analysis and relevant biological data of
possibly hazardous compounds.
Volume 13 continues the good job of
bringing together the previously scattered
data, and of giving a critical appraisal of
experiments, on the basis of numbers of ani-
mals, duration etc. In many cases there are
insufficient data for an evaluation of carcino-
genicity, and the working group obviously
has a difficult task. Nevertheless, the title of
the series leads one to expect some attempt
at evaluation of the risk to man. The IARC
state that "at the present time no attempt
can be made to interpret the animal data
directly in terms of human risk". However,
there are those, including some members of
the working group, who think that an attempt
at a tentative evaluation of the relative
degrees of risk could be made. For example,
it is generally agreed that induction of
liver-cell cancer in rats is more cause for
concern than induction of hepatomas in
mice. In practice, people with varying
degrees of understanding of the subject are
compelled to make decisions concerning
exposure at the present time, before adequate
data are available for firm evaluation of
risks. The opinions of the working group of
experts, in these situations, would be very
valuable.
Possibly the most widely used of the drugs
included in Volume 13 are phenacetin, pheno-
barbital and phenylbutazone. It is astonishing
that no data are available from carcino-
genicity studies in animals for a drug as
widely used as is phenylbutazone. Also, the
fact that the drug has 129 different names is
possibly not an ideal situation. Several
compounds considered in Volume 13 are car-
cinogenic for animals, but there is no firm
evidence that any of them, with the excep-
tions of phenacetin and phenytoin, are
carcinogenic for man under the conditions
used. Given the data, such as they are, the
reader is left to make his own evaluations.
V. M. CRADDOCK
Trends in Childhood Cancer. Ed M. H.
DONALDSON and H. G. SEYDEL (1976).
New York: John Wiley & Sons. 144 pp.
£12.40 net.
The proceedings of the 5th annual sympo-
sium on children's tumours, organised by the
Division of Oncology of the Children's
Hospital ofPhiladelphia and the Department
of Radiation Therapy of the American
Oncological Hospital of the Fox Chase
Cancer Centre, are published in this volume.
The contributors to the symposium are all
well known workers in the field of paediatric
oncology.
All the contributions are w%ell written and
contain some useful information. I was
particularly pleased to read the paper
drawing attention to the importance of
studying the later effects of treatment on the
developing child and of devising ways to
manage these effects, now that more and more
children are being cured of their malignancy.
Equally important was the multidisciplinary
approach and the need for hiigh standards of
service, both for diagnosis and management.
The two contributions on genetic, familial
and environmental causes and the relation-
ship of cancer to immunological changes,
summarise our present knowledge.
There are several papers on the manage-
ment of lymphomas and leukaemias, with a
particularly monumental one on the radio-
therapy of the lymphomas. Taken together
they give good indications of the uses of
chemiotherapy, radiotherapy and immuno-
therapy in these conditions.
The remaining papers deal mainly with
some of the solid tumours. Those on Ewing's
rhabdomyosarcoma and Wilms' tumour de-
scribe the present situation in terms of the
management of these tumours, but the last
two deal with results rather vaguely. The
papers on neuroblastoma and retinoblastoma
on the other hand, successfully cover our
knowledge and management of these two
interesting tumours.
This was obviously an interesting sym-
posium, and it is useful to have these papers
collected into one volume, but its presentation324 BOOK REVIEWS
in hard-back form makes it expensive for the
information it contains.
D. PEARSON
Chemotherapy of Solid Tumours-
Report of a WHO Expert Committee.
Technical Report Series 605. (1977).
106 pp. Sw. fr. 10.00 net. U.S.$4.00 net.
This book is one of a series of reports pro-
duced by WHO Expert Committees. The
members are eminent chemotherapists chosen
fromaround the world; the excellence oftheir
knowledge is reflected in both the compre-
hensiveness and relatively up-to-date content.
However, the reviewer questions the value
of such books and wonders to which readers
it is directed. The volume is not large enough
to be a text book on chemotherapy.
It is perhaps to be regarded as an intro-
duction to chemotherapy for those who are
not practising it. There appears to have been
a regrettable lack of radiotherapeutic advice
in the preparation ofthis document, resulting
in one or two lapses inthetext, asindiscussing
Methotrexate and Razoxane as radiosensiti-
sers.
The report is well written.
N. M. BLEEHEN
Pathology of Tumours in Laboratory
Animals Vol. 1.-Tumours of the Rat,
Part 2. Ed. V. S. TURUSOV (1976). Lyon:
International Agency for Research on
Cancer. 319 PP. U.S.$35.00 net.
This part of Tumours of the Rat includes
chapters on the respiratory tract, liver,
urogenital system, pituitary, thyroid, adrenal,
central and peripheral nervous systems and
the heart. As with Part 1, the aim is to
establish a standardized terminology in the
field of tumours in laboratory rats. This
volume will go some way towards this, but
there are obvious differences in nomenclature
depending on the source of material. In most
chapters there is a brief description of the
normal structure of the organ. As a result of
their brevity these are of limited use, and in
some instances omit important features or
may be misleading. On nomenclature, these
volumes are internally inconsistent. For
example, a "benign hepatoma" is described
in the liver, while in the 1968 IARC publica-
tion No. 1 on Liver Cancer there was a
recommendation that this term should not be
used. In the present volume it is being used
to designate a "benign neoplasm" while
there is an editor's note that the term
"hepatoma" in the volume on tumours of the
mouse is used for both benign and malignant
liver tumours. This is just one example of
inconsistency. Many of the chapters give
excellent descriptions and illustrations of the
tumours, but others are less helpful due to
the brevity of the description, as in the
nervous system, or in the highly specialized
nature ofthe information, as in the pituitary.
For a volume such as this to be successful it is
important that the quality of illustration is
high. There has been considerable improve-
ment over Part 1, but much remains to be
done. For example, in the chapter ontumours
of the vagina the selected photographs are
often too small to be ofuse, and following the
excellent discussion of the thyroid, many of
the illustrations are of poor focus. A good
feature of this volume in general is that the
authors discuss the problems of differential
diagnosis and in particular often refer to the
problems in distinguishing hyperplasias from
neoplasias. This book can be recommended
as a most useful addition to the information
which is available on the tumours of labora-
tory animals.
W. H. BUTLER
Adjuvant Therapy of Cancer. Ed. S. E.
SALMON and S. E. JONES (1977). Amster-
dam: Elsevier/North-Holland. 646 pp.
U.S.$53.95 net.
This is an excellent publication, dealing
with a subject that is currently occupying
the minds of very many clinical oncologists.
Chemotherapy has passed through several
phases, notably those ofthe single agent and,
later, of the proliferation ofever more exotic
combinations for the treatment of advanced
malignancy. Adjuvant chemotherapy is the
phase of the moment. It is likely (though
even this is being questioned) that chemo-
therapy is most effective when there is a
small body-burden of tumour (i.e. micro-
metastases) so it is very reasonable to offer
adjuvant treatment to high-risk patients in
this category. This book contains many papers
often of a very high standard, dealing with
clinical applications and results, but also